YAP1 and cardiac hypertrophy: Many unknowns remain, including the cellular and molecular mechanisms involved in the direct and indirect impact of metabolic reprogramming on cardiac hypertrophy and dysfunction; the potential role of altered metabolites as signaling molecules in addition to substrates for cellular growth; the differences in metabolic reprogramming under physiological versus pathological hypertrophy; and a proof-of-concept demonstration of YAP-targeted therapy in heart failure.